Niguidula N, Alamillo C, Shahmirzadi Mowlavi L, Powis Z, Cohen JS, Farwell Hagman KD. Clinical whole‐exome sequencing results impact medical management. Mol Genet Genomic Med. 2018;6:1068--1078. 10.1002/mgg3.484

1. INTRODUCTION {#mgg3484-sec-0005}
===============

For patients with genetic diseases, reaching a diagnosis brings an end to the expensive, time‐consuming, and potentially invasive diagnostic odyssey that burdens patients, families, and the healthcare system. Clinical whole‐exome sequencing (WES) is an effective diagnostic tool to pinpoint rare genetic alterations in an unbiased and efficient way for patients who have failed to receive a diagnosis despite extensive testing and workup. Several studies have shown that WES provides a diagnostic rate ranging from 25% to 40%, which is two to three times higher than traditional genetic testing methods.(Farwell et al., [2015](#mgg3484-bib-0003){ref-type="ref"}; Iglesias et al., [2014](#mgg3484-bib-0008){ref-type="ref"}; Lee et al., [2014](#mgg3484-bib-0011){ref-type="ref"}; Retterer et al., [2016](#mgg3484-bib-0017){ref-type="ref"}; Srivastava et al., [2014](#mgg3484-bib-0021){ref-type="ref"}; Yang et al., [2013](#mgg3484-bib-0027){ref-type="ref"}, [2014](#mgg3484-bib-0028){ref-type="ref"}, [2013](#mgg3484-bib-0027){ref-type="ref"}, [2014](#mgg3484-bib-0028){ref-type="ref"}) Recent publications have also demonstrated that if WES were used as a first‐tier test, there would be a substantial reduced time to diagnosis and it is only a half to one‐quarter the cost of traditional testing.(Joshi et al., [2016](#mgg3484-bib-0009){ref-type="ref"}; Monroe et al., [2016](#mgg3484-bib-0014){ref-type="ref"}; Neveling et al., [2013](#mgg3484-bib-0015){ref-type="ref"}; Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Stark et al., [2017](#mgg3484-bib-0022){ref-type="ref"}; Tan et al., [2017](#mgg3484-bib-0023){ref-type="ref"}; Vissers et al., [2017](#mgg3484-bib-0025){ref-type="ref"}).

An early and accurate molecular diagnosis can lead to optimal care and dramatic prognostic improvements for patients and their families.(Fan et al., [2014](#mgg3484-bib-0001){ref-type="ref"}; Fogel et al., [2014](#mgg3484-bib-0004){ref-type="ref"}; Hanchard et al., [2013](#mgg3484-bib-0006){ref-type="ref"}; Iglesias et al., [2014](#mgg3484-bib-0008){ref-type="ref"}; Sawyer et al., [2016](#mgg3484-bib-0018){ref-type="ref"}; Srivastava et al., [2014](#mgg3484-bib-0021){ref-type="ref"}; Worthey et al., [2011](#mgg3484-bib-0026){ref-type="ref"}) The clinical utility of WES has been measured by evaluating medical charts and HCP surveys to demonstrate the impact WES has on medical management and treatment strategies.(Hu et al., [2017](#mgg3484-bib-0007){ref-type="ref"}; Iglesias et al., [2014](#mgg3484-bib-0008){ref-type="ref"}; Meng et al., [2017](#mgg3484-bib-0012){ref-type="ref"}; Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Srivastava et al., [2014](#mgg3484-bib-0021){ref-type="ref"}; Tan et al., [2017](#mgg3484-bib-0023){ref-type="ref"}; Valencia et al., [2015](#mgg3484-bib-0024){ref-type="ref"}) The clinical factors measured include changes to family planning and testing, new specialist referrals, changes in patient care, medication or dietary changes, further diagnostic testing, enhanced surveillance, and prognosis expectations. HCPs typically order WES for a mix of phenotypes making follow‐up difficult across several disciplines and individual disease cohorts generally suffer from small sample sizes. Despite these limitations, clinical utility studies of pediatric neurodevelopmental disorders (NDDs), multiple congenital anomalies, and critically ill infants have reported a 26%--64% change in medical management for patients with positive WES results.(Hu et al., [2017](#mgg3484-bib-0007){ref-type="ref"}; Iglesias et al., [2014](#mgg3484-bib-0008){ref-type="ref"}; Meng et al., [2017](#mgg3484-bib-0012){ref-type="ref"}; Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Tan et al., [2017](#mgg3484-bib-0023){ref-type="ref"}; Valencia et al., [2015](#mgg3484-bib-0024){ref-type="ref"}).

In this study, we evaluated the clinical utility of WES by surveying HCPs about changes in clinical management subsequent to receiving their patient\'s WES test results. The survey gathered information from the ordering HCP about changes in medication and treatment plans, prognosis and risk assessment, reproductive planning, and educational services subsequent to WES testing.

2. MATERIALS AND METHODS {#mgg3484-sec-0006}
========================

2.1. Ethical compliance {#mgg3484-sec-0007}
-----------------------

Solutions Institutional Review Board approved this study by expedited review. Retrospective data analysis of anonymized data exempted the study from the requirement to receive consent from patients.

2.2. Clinical samples {#mgg3484-sec-0008}
---------------------

The study gathered information from HCPs who had referred their patients for WES via a post‐test survey (Supporting information Figure [S1](#mgg3484-sup-0001){ref-type="supplementary-material"}). A total of 2,876 surveys were sent out between 27 May 2015 and 16 December 2016 and were attached to the end of the WES report. The only inclusion criterion was that the patient underwent WES testing at one commercial testing laboratory during this time frame. If a patient opted to obtain secondary findings in addition to the primary results from the WES test, the HCP was asked to answer the same set of questions specifically in regard to the patient\'s secondary finding results. The responses from the survey were linked to the patient\'s demographic information and WES results to account for patient indications, clinical features, and results. We offered a minimal incentive to the HCP to complete the survey; HCPs who completed a survey were entered into a drawing to win a \$100 gift card to Amazon.com. Once the survey was closed and all data were collected, patient identifiers were removed for the study. The clinical histories provided by the referring HCP for each patient were carefully summarized and tabulated by a genetic counselor. The following data points were included age of the proband at the date of sample receipt, gender, consanguinity, previous clinical and/or differential diagnoses, a short clinical synopsis, family history, and an 18‐category organ system(s) involvement categorization. The genetic counselor also determined whether the proband had intellectual disability (ID), a positive brain magnetic resonance imaging (MRI) result, multiple congenital anomalies, seizures/epilepsy, ataxia, autism spectrum disorder, or psychiatric disease.

2.3. Exome sequencing, analysis, and reporting {#mgg3484-sec-0009}
----------------------------------------------

Exome library preparation, sequencing, bioinformatics, and analysis were performed as previously described.(Farwell et al., [2015](#mgg3484-bib-0003){ref-type="ref"}; Farwell Hagman et al., [2016](#mgg3484-bib-0002){ref-type="ref"}) WES reports with findings in clinically characterized genes were classified into four categories based on the combined assessment of the pathogenicity of the variant along with the level of clinical correlation between the proband\'s phenotype with gestalt of symptoms typically associated with the reported gene(s): (a) positive: relevant alteration(s) detected; (b) likely positive: relevant alteration(s) detected; (c) uncertain: alteration(s) of uncertain clinical relevance detected; and (d) negative: no relevant alterations detected. If either the phenotypic overlap or the deleterious nature of the alterations was classified as uncertain, then the overall WES result category was uncertain. WES reports with findings in novel candidate genes, which are always reported as uncertain findings, were classified into two categories: (a) candidate or (b) suspected candidate, as previously described.(Farwell Hagman et al., [2016](#mgg3484-bib-0002){ref-type="ref"}).

3. RESULTS {#mgg3484-sec-0010}
==========

3.1. Demographics and clinical indications {#mgg3484-sec-0011}
------------------------------------------

A total of 2,876 surveys were requested and 62 (2.2%) completed surveys were returned to the clinical laboratory. The patient demographics included 28 (45.2%) female patients and 34 (54.8%) male patients, with a median age of 5.5 years at the time of sample submission (Table [1](#mgg3484-tbl-0001){ref-type="table"}). The majority of patients were under age 5 years (48.5%), and the remaining patients were between age 6--18 years (33.8%), age 21--82 years (17.7%), and prenatal (3.2%). The indications for WES testing included a wide range of clinical phenotypes and are representative of WES ordering patterns in general. Patients with non‐specific and complex NDD were the most prevalent (33.9%, 21/62) indication. Multiple congenital anomalies (8.1%), cancer susceptibility (6.5%), movement disorders (4.8%), and cardiovascular symptoms (4.8%) were also reported phenotypes of the patients included in the study cohort.

###### 

Demographics

                                                          *N*   \%
  ------------------------------------------------------- ----- ------
  Age                                                           
  Prenatal                                                2     3.2
  Age \<5 year                                            29    45.3
  Age 6--18 year                                          22    33.8
  Adults                                                  11    17.7
  Gender                                                        
  Male                                                    34    54.8
  Female                                                  28    45.2
  Primary reason for referral                                   
  Neurodevelopmental                                      21    33.9
  Multiple congenital anomalies                           5     8.1
  Intellectual disability                                 5     8.1
  Seizure                                                 5     8.1
  Cancer susceptibility                                   4     6.5
  Brain abnormalities                                     4     6.5
  Autism                                                  3     4.8
  Movement disorder                                       3     4.8
  Cardiovascular                                          3     4.8
  Neuromuscular                                           2     3.2
  Skeletal                                                2     3.2
  Ataxia/spasticity                                       1     1.6
  Hematologic                                             1     1.6
  Immune                                                  1     1.6
  Undergrowth/failure to thrive                           1     1.6
  Mixed phenotype: cancer, multiple congenital disorder   1     1.6
  Primary results                                               
  Positive                                                23    37.1
  Uncertain                                               6     9.7
  Negative                                                32    51.6
  Novel                                                   1     1.6
  Secondary findings                                            
  ACMG negative                                           53    85.5
  ACMG positive                                           2     3.2
  Not tested                                              7     11.3
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3.2. Exome sequencing diagnoses {#mgg3484-sec-0012}
-------------------------------

Of the 62 HCPs that responded to the survey, 37.1% (23) were from patients with a positive or likely positive pathogenic alteration, 51.6% (32) had no relevant gene findings, 9.7% (6) had uncertain findings, and 1 patient (1.6%) had a novel candidate finding (Table [1](#mgg3484-tbl-0001){ref-type="table"}). These detection rates are representative of WES in general and are not statistically different than those we have previously reported (Farwell et al., [2015](#mgg3484-bib-0003){ref-type="ref"}) (chi‐square 4 × 2 contingency table *p* = 0.206509). Exome sequencing identified 26 unique variants in the 23 patients with positive or likely positive results. The majority of the patients (60.9%) presented with atypical and overlapping neurodevelopmental or neuromuscular disorder symptoms. Of the 26 pathogenic variants identified, six were inherited from a parent, 16 variants were de novo, and four were likely de novo alterations but could not be determined because the father was not tested. One patient had two pathogenic alterations in two different genes (Table [2](#mgg3484-tbl-0002){ref-type="table"}).

###### 

Positive and uncertain cases

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age (years)   Primary reason for referral                            Primary results                                         Gene                                                                                                             Molecular diagnosis
  ------------- ------------------------------------------------------ ------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  prenatal      Cardiovascular                                         Positive                                                *AARS2* (OMIM\#612035; GenBank RefSeq [NG_031952.1](NG_031952.1))                                                Combined oxidative phosphorylation deficiency 8

  3             Intellectual disability                                Positive                                                *FOXP1* (OMIM\#605515; GenBank RefSeq [NG_028243.1](NG_028243.1))                                                Intellectual disability with language impairment and with or without autistic features

  3             Intellectual disability                                Positive                                                *SYNGAP1* (OMIM\#603384; GenBank RefSeq [NG_016137.2](NG_016137.2))                                              Mental retardation, autosomal dominant 5

  2             Multiple congenital anomalies                          Positive                                                *FBN1* (OMIM\#134797; GenBank RefSeq [NG_008805.2](NG_008805.2))                                                 Type 1 Fibrillinopathy

  10            Multiple congenital anomalies                          Positive                                                *KAT6B* (OMIM\#605880; GenBank RefSeq [NG_032048.1](NG_032048.1))                                                Genitopatellar/Say‐Barber‐Biesecker‐Young‐Simpson syndrome

  2             Multiple congenital anomalies                          Partial positive                                        *ACTG2* (OMIM\#102545; GenBank RefSeq [NG_034140.1](NG_034140.1))                                                Visceral myopathy

  2             Neurodevelopmental                                     Positive                                                *SLC16A2* (OMIM\#300095; GenBank RefSeq [NG_011641.1](NG_011641.1))                                              Allan‐Herndon‐Dudley syndrome

  2             Neurodevelopmental                                     Positive                                                *TCF4* (OMIM\#602272; GenBank RefSeq [NG_011716.2](NG_011716.2))                                                 Pitt‐Hopkins syndrome

  8             Neurodevelopmental                                     Likely positive                                         *EP300* (OMIM\#602700; GenBank RefSeq [NG_009817.1](NG_009817.1))                                                Rubinstein‐Taybi syndrome

  2             Neurodevelopmental                                     Likely positive                                         *DDX3X* (OMIM\#300160; GenBank RefSeq [NG_012830.2](NG_012830.2))                                                X‐linked intellectual disability 102

                                                                       Positive                                                *RAI1* (OMIM\#607642; GenBank RefSeq [NG_007101.2](NG_007101.2))                                                 Smith‐Magenis syndrome

  1             Neurodevelopmental                                     Positive                                                *MECP2* (OMIM\#300005; GenBank RefSeq [NG_007107.2](NG_007107.2))                                                Encephalopathy, neonatal severe

  4             Neurodevelopmental                                     Positive                                                *KDM5C* (OMIM\#314690; GenBank RefSeq [NG_008085.2](NG_008085.2))\                                               X‐linked Claes‐Jensen type syndromic mental retardation, Lynch syndrome
                                                                                                                               *MSH6* [\[Link\]](#mgg3484-note-0001){ref-type="fn"} (OMIM\#600678; GenBank RefSeq [NG_007111.1](NG_007111.1))   

  3             Neurodevelopmental                                     Positive                                                *SLC2A1* (OMIM\#138140; GenBank RefSeq [NG_008232.1](NG_008232.1))                                               Stomatin‐deficient cryohydrocytosis with neurologic defects

  21            Neurodevelopmental                                     Positive                                                *FOXP1* (OMIM\#605515; GenBank RefSeq [NG_028243.1](NG_028243.1))                                                Intellectual disability with language impairment and with or without autistic features

  14            Neurodevelopmental                                     Positive                                                *ANKRD11* (OMIM\#611192; GenBank RefSeq [NG_032003.1](NG_032003.1))                                              KBG syndrome

  2             Neurodevelopmental                                     Positive                                                *SCN8A* (OMIM\#600702; GenBank RefSeq [NG_021180.2](NG_021180.2))                                                Epileptic encephalopathy, early infantile, 13

  1             Neurodevelopmental                                     Positive                                                *GABBR2* (OMIM\#607340; GenBank RefSeq [NG_016426.1](NG_016426.1))                                               GABBR2‐related neurodevelopmental disorder

  7             Neurodevelopmental                                     Positive                                                *UBE3A* (OMIM\#601623; GenBank RefSeq [NG_009268.1](NG_009268.1))                                                Angelman syndrome

  17            Neurodevelopmental                                     Positive                                                *PMM2* (OMIM\#601785; GenBank RefSeq [NG_009209.1](NG_009209.1))                                                 Congenital disorder of glycosylation, Type IA

  1 month.      Neuromuscular                                          Likely positive                                         *SOX10* (OMIM\#602229; GenBank RefSeq [NG_007948.1](NG_007948.1))                                                *SOX10*‐related peripheral demyelinating neuropathy

  4             Neuromuscular                                          Positive                                                *TPM3* (OMIM\#191030; GenBank RefSeq [NG_008621.1](NG_008621.1))                                                 *TPM3*‐related myopathy

  4             Seizures                                               Likely positive                                         *MEF2C* (OMIM\#600662; GenBank RefSeq [NG_023427.1](NG_023427.1))                                                Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations

  2             Cancer susceptibility, Multiple congenital disorders   Likely positive                                         *SMARCE1* (OMIM\#603111; GenBank RefSeq [NG_032163.1](NG_032163.1))                                              Coffin‐Sirissyndrome

                                                                       Expanded positive                                       *MSH6* (OMIM\#600678; GenBank RefSeq [NG_007111.1](NG_007111.1))                                                 Increased risk of Lynch syndrome

  4             Neurodevelopmental                                     Novel                                                   *ZBTB18* (OMIM\#608433; GenBank RefSeq [NG_033841.1](NG_033841.1))                                               *ZBTB18*‐related intellectual disability with hypogenesis of the corpus callosum

  5             Autism                                                 Uncertain                                               *IQSEC2* (OMIM\#300522; GenBank RefSeq [NG_021296.2](NG_021296.2))                                               

  1 month       Cardiovascular                                         Uncertain                                               *HCN4* (OMIM\#605206; GenBank RefSeq [NG_009063.1](NG_009063.1))                                                 

  23            Movement disorder                                      Uncertain                                               *TPK1* (OMIM\#606370; GenBank RefSeq [NG_032112.1](NG_032112.1))                                                 

  11            Neurodevelopmental                                     Uncertain                                               *SCN8A* (OMIM\#600702; GenBank RefSeq [NG_021180.2](NG_021180.2))                                                

  8             Seizures                                               Uncertain                                               *DCX* (OMIM\#300121; GenBank RefSeq [NG_011750.1](NG_011750.1))                                                  

  11            Seizures                                               Uncertain                                               *SETBP1* (OMIM\#611060;GenBank RefSeq [NG_027527.2](NG_027527.2))                                                

  7             Undergrowth                                            Positive[\[Link\]](#mgg3484-note-0001){ref-type="fn"}   *CACNA1S* (OMIM\#114208; GenBank RefSeq [NG_009816.1](NG_009816.1))                                              Increased risk of malignant hyperthermia
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Secondary finding.
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3.3. Effect of WES on clinical management {#mgg3484-sec-0013}
-----------------------------------------

To demonstrate the clinical utility of WES, we surveyed HCPs on 18 components of medical management, reproductive planning, and educational services after receiving a WES report. Overall, irrespective of WES results, 67.7% (42/62) of the HCPs responded positively to at least one of the 18 queries. When stratified by WES results, 100% of the HCPs of patients with positive or likely positive WES results (*n* = 23) and 100% of HCPs of patients with uncertain WES results (*n* = 7) responded positively to one of the 18 queries. Notably, 37.5% (12/32) of the HCPs of patients with negative WES results also responded positively to at least one query. To better evaluate the results, the survey was divided into five categories: (a) medication changes, (b) discontinuation of diagnostic testing, (c) medical management changes, (d) availability of psychosocial services, and (e) reproductive planning changes. Each of the five categories had two to five queries each (Supporting information Figure [S1](#mgg3484-sup-0001){ref-type="supplementary-material"}), and the results are summarized in Figure [1](#mgg3484-fig-0001){ref-type="fig"}.

![Medical management changes based on WES results. The survey results of the five categories of medical management stratified by the exome sequencing result. The percentage is based on the number of cases that responded positively to one of the queries within a specific category](MGG3-6-1068-g001){#mgg3484-fig-0001}

To demonstrate the impact WES specifically had on medical management, we grouped together the survey results from categories 1--3 (medication changes, discontinuation of further diagnostic studies, and medical management changes). Irrespective of the exome result, 64.5% (40/62) of the HCPs responded positively to a query within one of those three categories. When stratifying by WES result, the medical management changes for the patients with positive WES results, negative WES results, and uncertain WES results were 100%, 100%, and 31.3%, respectively.

3.4. Medication changes {#mgg3484-sec-0014}
-----------------------

Based on the surveys from HCPs of patients who received a positive WES result, 17.4% reported a change in medication (Table [3](#mgg3484-tbl-0003){ref-type="table"}). The HCP for a patient with a dual diagnosis (X‐linked ID \[*OMIM\#300160\]* and Smith‐Magenis syndrome \[*OMIM\#607642\]*) responded positively to all three queries: new medication, discontinued unnecessary medication, and discontinued medication due to adverse effects. A patient with multiple congenital anomalies and a positive WES result qualified for a clinical trial and new treatments. One patient with a positive finding was prescribed a new ketogenic diet to reduce seizures based on the diagnosis of neurologic defects with stomatin‐deficient cryohydrocytosis (*OMIM\#138140*). Interestingly, one patient with a negative result (3.1%) also had a medication change. The patient\'s indication for testing was suspected inherited skeletal syndrome and the negative result allowed the HCP to discontinue the patient\'s specialized ketogenic diet, presumably due to a ruled out differential diagnosis. Additionally, two HCPs of patients who received an uncertain WES result reported a new medication prescription.

###### 

Survey results

                                                  Positive patients   Uncertain patients[\[Link\]](#mgg3484-note-0002){ref-type="fn"}   Negative patients
  ----------------------------------------------- ------------------- ----------------------------------------------------------------- -------------------
  New medication                                  4 (17.4%)           2 (28.6%)                                                         0%
  Discontinue unnecessary medication              1 (4.3%)            0%                                                                1 (3.1%)
  Discontinue medication with adverse effects     1 (4.3%)            0%                                                                0%
  Discontinue diagnostic studies                  15 (65.2%)          4 (57.1%)                                                         4 (12.5%)
  Discontinue genetic testing                     21 (91.3%)          6 (85.7%)                                                         8 (25%)
  Referral to additional specialist               12 (52.2%)          2 (28.6%)                                                         3 (9.4%)
  Investigate additional manifestations           13 (56.5%)          2 (28.6%)                                                         1 (3.1%)
  Enhanced surveillance/prophylactic surgery      7 (30.4%)           3 (42.9%)                                                         0%
  Change prognosis expectations                   14 (60.9%)          3 (42.9%)                                                         1 (3.1%)
  Availability of clinical trial                  4 (17.4%)           0%                                                                0%
  Referral to support group                       13 (56.5%)          1 (14.3%)                                                         0%
  Availability of additional education services   12 (52.2%)          2 (28.6%)                                                         0%
  Altered family financial planning               3 (13%)             0%                                                                0%
  Changed presumed inheritance pattern            9 (39.1%)           0%                                                                1 (3.1%)
  Established accurate recurrence risks           19 (82.6%)          2 (28.6%)                                                         1 (3.1%)
  Enabled reproductive planning options           11 (47.8%)          2 (28.6%)                                                         1 (3.1%)
  Gained option for carrier testing               4 (17.4%)           3 (42.9%)                                                         0%
  Enabled earlier diagnosis of relative           4 (17.4%)           2 (28.6%)                                                         1 (3.1%)

Including one patient with a novel finding.
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3.5. Discontinuation of diagnostic testing {#mgg3484-sec-0015}
------------------------------------------

Of the patients with positive WES results in this study, 65.2% of the HCPs reported a discontinuation of further diagnostic studies and 91.3% discontinued additional genetic tests (Table [3](#mgg3484-tbl-0003){ref-type="table"}). In a patient with global developmental delay and spastic cerebral palsy who received an Allan‐Herndon‐Dudley syndrome (*OMIM\#300095)* diagnosis, the ordering HCP commented that the exome test "ended the very aggressive diagnostic efforts" and the patient qualified for a clinical trial (Table [4](#mgg3484-tbl-0004){ref-type="table"}). Among HCP surveys from patients with negative WES results, 12.5% discontinued further diagnostic studies and 25% discontinued genetic testing. A patient with NDD who received a negative WES result was able to narrow the diagnostic studies to additional enzyme activity and metabolic tests (Table [4](#mgg3484-tbl-0004){ref-type="table"}). Nearly, all (85.7%) of the seven HCPs of patients with uncertain WES results discontinued genetic testing and 57.1% discontinued further diagnostic studies. The HCP of a patient with a complex epilepsy phenotype and an uncertain WES finding commented that the "test result ended their patient\'s diagnostic odyssey" which included NDD and neuromuscular assessments, five genetic tests, microarray, MRI, and metabolic panel testing (Table [4](#mgg3484-tbl-0004){ref-type="table"}). The HCP of a patient with cardiovascular symptoms reported ordering additional deletion/duplication testing for one gene after receiving the uncertain WES result. The HCP of the patient with a novel finding responded that based on the WES result, they were able to discontinue any further diagnostic or genetic testing.

###### 

Additional comments from referring providers

  Age (years)   Results           Gene        Primary reason for referral     Provider comments
  ------------- ----------------- ----------- ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1 month       Uncertain         *HCN4*      Cardiovascular                  "Parents were very relieved the results are likely de novo and no apparent ID associated with mutation found. Further testing for a deletion or duplication of the gene."
  2             Positive          *ACTG2*     Multiple congenital anomalies   "The patient is now a candidate for a transplant."
  1             Positive          *MECP2*     Neurodevelopmental              "Allowed for palliative care and end‐of‐life decisions to be discussed more thoroughly."
  2             Positive          *SLC16A2*   Neurodevelopmental              "This test stopped very aggressive diagnostic efforts, qualified him for a clinical trial, and there are other treatments that he is now receiving. The parents also benefited from knowing the mechanism of inheritance."
  1             Positive          *GABBR2*    Neurodevelopmental              "We are pleased to have additional information that will help us in the future for care."
  2             Positive          *SCN8A*     Neurodevelopmental              "Neurology may recommend medication changes."
  3             Positive          *SLC2A1*    Neurodevelopmental              "New dietary recommendations. We will start her on ketogenic diet to reduce/control seizures and the movement disorder."
  1 month       Likely positive   *SOX10*     Neuromuscular                   "The test provided clarification of prognosis expectations and helped to make decisions regarding care and long term."
  11            Uncertain         *SETBP1*    Seizures                        "This test result ended the patient\'s diagnostic odyssey. There is no longer a need for unnecessary tests and the family can finally move on."
  4             Negative          N/A         Autism                          "The result affected the diagnostic direction."
  27            Negative          N/A         Cancer susceptibility           "We will now pursue research testing."
  17            Negative          N/A         Immune                          "The results helped to suggest that the symptoms are more likely viral than genetic or hereditary."
  16            Negative          N/A         Intellectual disability         "The patient is now eligible to enroll in the CURE\'s Epilepsy Genetics Initiative."
  11            Negative          N/A         Neurodevelopmental              "The results help direct the ordering of additional tests to evaluate variants (e.g. enzyme assay for *MANBA* and transferrin testing for *COG1*‐CDG)."
  41            Negative          N/A         Skeletal                        "The report allowed for the discontinuation of specialized diet and enabled reassurance to a 1st degree relative concerned about a genetic disorder."

The *MANBA* gene codes for the beta‐mannosidase metabolizing enzyme.

COG1‐CDG; *COG1* gene‐related congenital disorders of glycosylation.
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3.6. Medical management changes {#mgg3484-sec-0016}
-------------------------------

Based on the surveys from the HCPs of the patients with a positive or likely positive WES result, 78.3% reported a change in medical management (Figure [1](#mgg3484-fig-0001){ref-type="fig"}). More than half of the HCPs of patients who received a definitive molecular diagnosis were able to refer the patient to an additional specialist (52.2%), investigate additional manifestations (56.5%), and/or changed the patient\'s prognosis (60.9%). A third (30.4%) of the HCPs of patients with positive WES results enhanced surveillance or opted for prophylactic surgery, and 17.4% identified the patient\'s eligibility for a clinical trial (Table [3](#mgg3484-tbl-0003){ref-type="table"}). The HCP of a patient who received a diagnosis of severe neonatal encephalopathy commented that the family was able to change their prognosis expectations since the exome result "allowed for palliative care and end‐of‐life decisions to be discussed more thoroughly" (Table [4](#mgg3484-tbl-0004){ref-type="table"}). The HCP of a patient with multiple congenital anomalies who received a visceral myopathy diagnosis commented that the WES result affected the patient\'s eligibility as a transplant candidate. The HCP of the patient with a novel finding only responded to one medical management query which was a new referral to an additional specialist.

Of the seven patients with uncertain WES results, five (71.5%) of their HCPs reported a change to their medical management. Despite receiving an uncertain finding, the HCP of one patient reported that the patient underwent four of the five medical management changes. Two additional patients with uncertain WES results began an enhanced surveillance strategy, and another patient\'s family responded that the uncertain result prompted a change in prognosis expectations. Based on the surveys from HCP of patients with negative WES results, two patients had a change in medical management and three patients were referred to additional specialists. The HCP of a 3‐year‐old man with autistic symptoms commented that the negative WES result "affected the diagnostic direction" and referred the patient to an additional specialist for the investigation of other manifestations (Table [4](#mgg3484-tbl-0004){ref-type="table"}). The HCP of a patient with an immune disorder and a negative WES result commented that the report "helped to suggest that the symptoms were more likely viral than of genetic origin". A patient with a negative WES result, a 15‐year‐old patient with developmental delays, autism, gastrointestinal issues, and a history of seizures, did not have any of the survey queries answered, but the HCP commented that "the patient is now eligible to enroll in the CURE\'s Epilepsy Genetics Initiative."

3.7. Availability of psychosocial services {#mgg3484-sec-0017}
------------------------------------------

In the psychosocial services component of the survey, 65.2% of the HCPs of patients with positive WES results responded positively to one of the three queries (Figure [1](#mgg3484-fig-0001){ref-type="fig"}). Over half were referred to a support group (56.5%) and/or additional educational services (52.2%); however, only a few (13%) responded that their patient\'s families altered their financial planning (Table [3](#mgg3484-tbl-0003){ref-type="table"}). None of the HCPs of patients with negative WES results reported the use of psychosocial services, while two of the seven HCPs of patients with uncertain results referred the patient to a support group and/or utilize educational services.

3.8. Reproductive planning changes {#mgg3484-sec-0018}
----------------------------------

Irrespective of exome result, 45.2% of the cohort was able to initiate new reproductive planning options. Of the families of patients with positive WES results, the HCPs were able to establish accurate recurrence risks (82.6%), enable reproductive planning options (47.8%), and change the presumed inheritance pattern (39.1%). Additionally, 17.4% of the HCPs of patients with positive WES results provided the option for carrier testing of family members and 13% enabled the earlier diagnosis of an affected/asymptomatic relative (Table [3](#mgg3484-tbl-0003){ref-type="table"}). The HCPs of six patients (85.7%) with uncertain WES results responded positively to one of the five reproductive planning queries. The HCP of a 7‐year‐old patient with seizures and an uncertain finding responded positively to four of the five reproductive planning questions. The HCP of an infant with cardiovascular anomalies and an uncertain exome result reported that reproductive planning options were now available for the family and that the "parents were relieved that it was a likely de novo variant and no variants were found associated to an ID" (Table [4](#mgg3484-tbl-0004){ref-type="table"}). The HCPs of two patients (6.3%) with negative WES results responded positively to at least one of the reproductive planning queries. The HCP of a prenatal patient with negative WES results and multiple congenital disorders responded that the family was able to change the presumed inheritance pattern, establish recurrence risks, and enabled their reproductive planning options.

3.9. Secondary findings {#mgg3484-sec-0019}
-----------------------

The American College of Medical Genetics and Genomics (ACMG) published a list of 59 known pathogenic or expected pathogenic genes that should be reported as incidental or secondary findings when clinical laboratories perform exome sequencing, even when unrelated to the primary medical reason for testing.(Green et al., [2013](#mgg3484-bib-0005){ref-type="ref"}; Kalia et al., [\[Link\]](#mgg3484-bib-0010){ref-type="ref"}) Additionally, our laboratory offers expanded secondary findings options from among \~1,200 genes.(Shahmirzadi et al., [2014](#mgg3484-bib-0019){ref-type="ref"}) Of the 56 patients that opted for secondary findings results, two patients (3.6%) were identified with positive results: one result (1.8%) within one of the ACMG recommended secondary findings genes and one result (1.8%) within one of our databases expanded secondary findings genes (Tables [1](#mgg3484-tbl-0001){ref-type="table"} and [2](#mgg3484-tbl-0002){ref-type="table"}). A 6.5 year old patient presenting with undergrowth or failure to thrive had a negative primary WES result; yet, a secondary finding was identified in *CACNA1S* (OMIM \#114208; GenBank RefSeq [NG_009816.1](NG_009816.1)). The HCP responded in the survey that the primary result provided no significant changes in medical care, but the secondary findings enabled an earlier diagnosis of an affected/asymptomatic relative. The second patient was a 4.1 year old with a NDD whose primary result (*KDM5C;* OMIM \#314690; GenBank RefSeq [NG_008085.2](NG_008085.2)) provided an X‐linked Claes‐Jensen syndrome diagnosis, and the secondary findings result indicated an increased risk of Lynch syndrome based on a pathogenic variant found in *MSH6* (OMIM \#600678; GenBank RefSeq [NG_007111.1](NG_007111.1)). The HCP responded that the primary results led to the discontinuation of further diagnostic and genetic tests, while the secondary result enabled an early diagnosis of an affected/asymptomatic relative and enhanced their surveillance strategy. The HCP also responded that both results changed the presumed inheritance pattern and allowed the option for carrier testing in family members.

4. DISCUSSION {#mgg3484-sec-0020}
=============

Of the surveys received, the majority of the patients had symptoms of complex NDDs, followed by patients with multiple congenital anomalies, ID, and seizures. The clinical characteristics of this cohort is similar to standard exome ordering patterns among patients referred to a commercial testing laboratory for WES with ID and/or developmental delay, positive brain MRI results, multiple congenital anomalies, and epilepsy (64%, 64%, 28%, and 24%, respectively; Farwell et al., [2015](#mgg3484-bib-0003){ref-type="ref"}).

WES has proven to be an effective diagnostic tool with demonstrated clinical validity, high diagnostic yield, and reduced time to diagnosis. A retrospective review of 40 pediatric patients referred for WES showed that 48% had at least four genetic tests prior to WES, and several patients had more than 10 genetic tests.(Valencia et al., [2015](#mgg3484-bib-0024){ref-type="ref"}) Several studies of pediatric NDDs or epilepsy patients have demonstrated a significant reduced time to diagnosis, with WES a diagnosis received in 3--5 months compared to 2--8 years with traditional methods.(Joshi et al., [2016](#mgg3484-bib-0009){ref-type="ref"}; Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Tan et al., [2017](#mgg3484-bib-0023){ref-type="ref"}; Vissers et al., [2017](#mgg3484-bib-0025){ref-type="ref"}; Yavarna et al., [2015](#mgg3484-bib-0029){ref-type="ref"}) Most importantly, two pediatric studies have shown that if WES were used as a first‐tier diagnostic test, 24%--64% of patients would have avoided invasive medical procedures.(Tan et al., [2017](#mgg3484-bib-0023){ref-type="ref"}; Vissers et al., [2017](#mgg3484-bib-0025){ref-type="ref"}) In this study, we surveyed the HCPs use of diagnostic procedures subsequent to WES testing. Overall, 95.7% of patients with positive WES results and 83.3% of patients with uncertain WES results were able to discontinue further diagnostic studies. While a negative result may be seen as somewhat uninformative, 25% of the HCPs of patients with negative WES results responded that they discontinued genetic testing specifically.

To demonstrate the impact WES specifically had on medical management, we grouped together the survey results from categories 1--3 (medication changes, discontinuation of further diagnostic studies, and medical management changes). Irrespective of the exome result, 64.5% (40/62) of the HCPs responded positively to a query within one of those three categories. One of the limitations of this study was that data were collected through December 2016, and clinical practices may have changed since then. Genes that were once considered uncertain may be pathogenic at this time and could impact HCP management decisions. While our results may be affected by survey bias based on the very low response rate (2%) and the HCPs who made changes in their patient\'s care may have been more motivated to complete and return the survey, our results are only slightly higher than results reported in similar publications. Previous studies of pediatric NDDs, multiple congenital anomalies, and critically ill infants have reported a 26%--52% change in medical management for patients with positive WES results.(Hu et al., [2017](#mgg3484-bib-0007){ref-type="ref"}; Meng et al., [2017](#mgg3484-bib-0012){ref-type="ref"}; Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Tan et al., [2017](#mgg3484-bib-0023){ref-type="ref"}) Studies that evaluated the clinical utility of WES diagnoses in pediatric and young adult cancer patients have observed similar rates (46%--75%) of clinical utility.(Mody et al., [2015](#mgg3484-bib-0013){ref-type="ref"}; Oberg et al., [2016](#mgg3484-bib-0016){ref-type="ref"}) In our cohort, more than half of HCPs of patients with positive WES results reported a referral to an additional specialist, investigating additional manifestations, and a change in prognosis. Our cohort observed a higher percentage of medical management changes compared to a similar pediatric NDD study where 12.5% of patients with positive WES results underwent disease monitoring, 18.8% underwent further clinical workup, and 31.3% altered their prognosis.(Srivastava et al., [2014](#mgg3484-bib-0021){ref-type="ref"}) In a WES study of 278 critically ill infants, the initiation of new specialist care was reported in 50.9%, the informed redirection of care was undertaken for 35.8%, and major procedures were ordered for 9.4% of patients with positive WES results (Meng et al., [2017](#mgg3484-bib-0012){ref-type="ref"}).

In the medication category, HCPs of patients who received a positive WES results, uncertain result, and negative result reported a change in care (17.4%, 33.3%, and 3.1%, respectively). These results are similar to pediatric studies of ID and NDDs with 21.9%--22.2% of patients with positive WES results reporting a new drug or dietary treatment.(Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Srivastava et al., [2014](#mgg3484-bib-0021){ref-type="ref"}) In the WES study of unrelated critically ill infants, 13.2% of patients with a definitive diagnosis altered their medication and/or dietary treatments (Meng et al., [2017](#mgg3484-bib-0012){ref-type="ref"}). Based on the patients with positive WES results in our cohort, 82.6% were given accurate recurrence risks, 47.8% were given reproductive planning options, and 39.1% were informed of a change in the presumed inheritance pattern. The Srivastava et al. study of pediatric ND patients (*n* = 78) is the only study that queried changes in reproductive planning changes. Of the 84.4% (27/32) patients with a positive WES diagnosis, the results were essential for reproductive planning and an additional seven (21.9%) patients changed their presumed inheritance pattern (Srivastava et al., [2014](#mgg3484-bib-0021){ref-type="ref"}).

While an uncertain or negative exome finding may seem uninformative, we are the first to demonstrate that these results have an impact on medical management. In this cohort, two patients with uncertain WES results started new medications and one patient with a negative WES result discontinued a specialized diet. Additionally, 66.7% of the patients with uncertain WES results had a change in clinical management and 9.4% of the patients with negative WES results were given a referral to an additional specialist. We also observed that patients with uncertain results were referred for psychosocial services, and the majority made reproductive planning changes. As noted in Table [4](#mgg3484-tbl-0004){ref-type="table"}, the HCPs of six patients with negative WES results and two patients with uncertain WES results provided additional comments on the impact WES testing had on their patient\'s medical management.

In the past few years, there has been a surge of WES publications demonstrating a higher diagnostic yield, reduced time to diagnosis, clinical utility, and cost‐effectiveness compared to the standard diagnostic pathway. (Farwell et al., [2015](#mgg3484-bib-0003){ref-type="ref"}; Iglesias et al., [2014](#mgg3484-bib-0008){ref-type="ref"}; Joshi et al., [2016](#mgg3484-bib-0009){ref-type="ref"}; Lee et al., [2014](#mgg3484-bib-0011){ref-type="ref"}; Monroe et al., [2016](#mgg3484-bib-0014){ref-type="ref"}; Neveling et al., [2013](#mgg3484-bib-0015){ref-type="ref"}; Retterer et al., [2016](#mgg3484-bib-0017){ref-type="ref"}; Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Srivastava et al., [2014](#mgg3484-bib-0021){ref-type="ref"}; Stark et al., [2017](#mgg3484-bib-0022){ref-type="ref"}; Tan et al., [2017](#mgg3484-bib-0023){ref-type="ref"}; Vissers et al., [2017](#mgg3484-bib-0025){ref-type="ref"}; Yang et al., [2013](#mgg3484-bib-0027){ref-type="ref"}, [2014](#mgg3484-bib-0028){ref-type="ref"} ) Several studies have evaluated the cost‐effectiveness for complex pediatric neurologic patients and demonstrate a 24%--40% reduction in diagnostic costs when using WES as a first‐tier test compared to traditional diagnostic methods.(Joshi et al., [2016](#mgg3484-bib-0009){ref-type="ref"}; Monroe et al., [2016](#mgg3484-bib-0014){ref-type="ref"}; Neveling et al., [2013](#mgg3484-bib-0015){ref-type="ref"}; Soden et al., [2014](#mgg3484-bib-0020){ref-type="ref"}; Vissers et al., [2017](#mgg3484-bib-0025){ref-type="ref"}) It is evident that the time and cost of uninformative tests in the traditional diagnostic pathway for complex NDDs and multiple congenital anomalies warrant WES as a first‐tier test. In this study, we demonstrate 100% clinical utility of WES based on HCP surveys of patients with positive or uncertain WES results among an unbiased cohort of patients referred for WES. Additionally, we are the first to demonstrate that even negative WES results have an impact on medical management. Collectively, the WES studies that have evaluated the impact WES has on medical management and patient outcome clearly demonstrates the clinical utility of this diagnostic tool.
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